DISEASE INDICATIONS: Lung Cancer
MANUFACTURER: AstraZeneca AB
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Tagrisso is a medication used to treat non-small cell lung cancer with EGFR T790M mutation. It inhibits the activity of the EGFR protein, leading to cancer cell death.